J&J’s Dual-Targeting CAR T Hits 80% Complete Response in Early Lymphoma Study
Analysts at Truist Securities called J&J’s CAR-T readout “compelling,” noting that the efficacy figures could position the cell therapy as a formidable competitor to the current standard of care, Gilead’s Yescarta.
J&J’s Dual-Targeting CAR T Hits 80% Complete Response in Early Lymphoma Study Read More »
